Immunologic considerations in heart transplantation for congenital heart disease

Current Cardiology Reviews

Volumn 7, Issue 2, 2011, Pages 67-71

  Kaufman, Beth D ^a   Shaddy, Robert E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Allosensitization; Heart transplantation; Management; Pediatric; Rejection; Therapy

Indexed keywords

ALLOANTIBODY; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOBUTAMINE; DOPAMINE; HLA ANTIBODY; IMMUNOGLOBULIN; MILRINONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ALLOGRAFT; ALLOIMMUNITY; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN PRESENTING CELL; BLOOD FILTER; BLOOD TRANSFUSION; CARDIAC GRAFT REJECTION; CONGENITAL HEART DISEASE; DRUG DOSE INCREASE; EXCHANGE BLOOD TRANSFUSION; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSITIZATION;

ANTIBODIES; CHILD; DESENSITIZATION, IMMUNOLOGIC; GRAFT REJECTION; HEART DEFECTS, CONGENITAL; HEART DISEASES; HEART TRANSPLANTATION; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION IMMUNOLOGY;

EID: 80054091666     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340311797484204     Document Type: Review

References (44)

1. Shaddy RE, Hunter DD, Osborn KA, et al. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. Circulation 1996; 94: 1063-7.
2. Smith JD, Ogino H, Hunt D, Laylor RM, Rose ML, Yacoub MH. Humoral immune response to human aortic valve homografts. Ann Thorac Surg 1995;60:S127-30.
3. Hawkins JA, Breinholt JP, Lambert LM, et al. Class I and class II anti-HLA antibodies after implantation of cryopreserved allograft material in pediatric patients. J Thorac Cardiovasc Surg 2000; 119: 324-30.
4. Breinholt JP, 3rd, Hawkins JA, Lambert LM, Fuller TC, Profaizer T, Shaddy RE. A prospective analysis of the immunogenicity of cryopreserved nonvalved allografts used in pediatric heart surgery. Circulation 2000; 102: III 179-82.
5. Hooper DK, Hawkins JA, Fuller TC, Profaizer T, Shaddy RE. Prospective follow-up of panel reactive antibodies in children 5- Years following implantation of cryopresaerved allografts. The Journal of Heart and Lung Transplantation 2004; 23:S168.
6. Hawkins JA, Hillman ND, Lambert LM, et al. Immunogenicity of decellularized cryopreserved allografts in pediatric cardiac surgery: comparison with standard cryopreserved allografts. J Thorac Cardiovasc Surg 2003; 126: 247-52; discussion 52-3.
7. Meyer SR, Campbell PM, Rutledge JM, et al. Use of an allograft patch in repair of hypoplastic left heart syndrome may complicate future transplantation. Eur J Cardiothorac Surg 2005; 27: 554-60.
8. Tavakkol Z, Gelehrter S, Goldberg CS, Bove EL, Devaney EJ, Ohye RG. Superior durability of SynerGraft pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg 2005; 80: 1610-4.
9. Hopkins RA, Jones AL, Wolfinbarger L, Moore MA, Bert AA, Lofland GK. Decellularization reduces calcification while improving both durability and 1-year functional results of pulmonary homograft valves in juvenile sheep. J Thorac Cardiovasc Surg 2009; 137: 907-13, 13e1-4.
10. Schmitz-Rixen T, Megerman J, Colvin RB, Williams AM, Abbott WM. Immunosuppressive treatment of aortic allografts. J Vasc Surg 1988; 7: 82-92.
11. Wagner E, Roy R, Marois Y, Douville Y, Guidoin R. Fresh venous allografts in peripheral arterial reconstruction in dogs. Effects of histocompatibility and of short-term immunosuppression with cyclosporine A and mycophenolate mofetil. J Thorac Cardiovasc Surg 1995; 110: 1732-44.
12. Shaddy RE, Lambert LM, Fuller TC, et al. Prospective randomized trial of azathioprine in cryopreserved valved allografts in children. Ann Thorac Surg 2001; 71: 43-7; discussion 7-8.
13. Shaddy RE, Fuller TC, Anderson JB, et al. Mycophenolic mofetil reduces the HLA antibody response of children to valved allograft implantation. Ann Thorac Surg 2004; 77: 1734-9; discussion 9.
14. Anderson JB, Fuller TC, Hawkins JA, Brinkman MK, Profaizer T, Shaddy RE. Two-year reduction of panel reactive human leukocyte antigen antibodies in children receiving mycophenolate mofetil after valved allograft placement. Transplantation 2005; 80: 414-6.
15. Shaddy RE, Fuller TC. The sensitized pediatric heart transplant candidate: causes, consequences, and treatment options. Pediatr Transplant 2005; 9: 208-14.
16. Mitchell RN, Jonas RA, Schoen FJ. Pathology of explanted cryopreserved allograft heart valves: comparison with aortic valves from orthotopic heart transplants. J Thorac Cardiovasc Surg 1998; 115: 118-27.
17. Rajani B, Mee RB, Ratliff NB. Evidence for rejection of homograft cardiac valves in infants. J Thorac Cardiovasc Surg 1998; 115: 111-7.
18. Vogt PR, Stallmach T, Niederhauser U, et al. Explanted cryopreserved allografts: a morphological and immunohistochemical comparison between arterial allografts and allograft heart valves from infants and adults. Eur J Cardiothorac Surg 1999; 15: 639-44; discussion 44-5.
19. Lavee J, Kormos RL, Duquesnoy RJ, et al. Influence of panelreactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation. J Heart Lung Transplant 1991; 10: 921-9; discussion 9-30.
20. Kobashigawa JA, Sabad A, Drinkwater D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996; 94: II 294-7.
21. Feingold B, Bowman P, Zeevi A, et al. Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant 2007; 26: 565-71.
22. Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701-6.
23. Pollock-BarZiv SM, den Hollander N, Ngan BY, et al. Pediatric heart transplantation in human leukocyte antigen sensitized patients: evolving management and assessment of intermediateterm outcomes in a high-risk population. Circulation 2007; 116: I172-8.
24. Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876-82.
25. Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002; 105: 1214-9.
26. Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008; 359: 242-51.
27. John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-HLA alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: II 229-35.
28. Hammond EH, Ensley RD, Yowell RL, et al. Vascular rejection of human cardiac allografts and the role of humoral immunity in chronic allograft rejection. Transplant Proc 1991; 23: 26-30.
29. Rose EA, Pepino P, Barr ML, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992; 11: S120-3.
30. Itescu S, Tung TC, Burke EM, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786-93.
31. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58-69.
32. Ho EK, Vlad G, Vasilescu ER, et al. Pre- and posttransplantation allosensitization in heart allograft recipients: Major impact of de novo alloantibody production on allograft survival. Hum Immunol 2010.
33. Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgartner WA, Conte JV. Influence of pretransplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007; 84: 1556-62; discussion 62-3.
34. Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004; 78: 1703-9.
35. Di Filippo S, Girnita A, Webber SA, et al. Impact of ELISAdetected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol 2005; 66: 513-8.
36. Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti- HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 1289-96.
37. Rossano JW, Morales DL, Zafar F, et al. Impact of antibodies against human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network for Organ Sharing database. J Thorac Cardiovasc Surg 2010; 140: 694-9, 9 e1-2.
38. Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: Evolution and current status (2005-2011). J Heart Lung Transplant 2011; 30: 601-11.
39. Kfoury AG, Hammond ME. Controversies in defining cardiac antibody-mediated rejection: need for updated criteria. J Heart Lung Transplant 2010; 29: 389-94.
40. Ho EK, Chan FL, Leong JC. Postsurgical recurrent stress fracture in the spine affected by ankylosing spondylitis. Clin Orthop Relat Res 1989: 87-9.
41. Nair N, Ball T, Uber PA, Mehra MR. Current and future challenges in therapy for antibody-mediated rejection. J Heart Lung Transplant 2011; 30: 612-7.
42. Singh N, Pirsch J, Samaniego M. Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) 2009; 23: 34-46.
43. Flechner SM, Fatica R, Askar M, et al. The Role of Proteasome Inhibition With Bortezomib in the Treatment of Antibody- Mediated Rejection After Kidney-Only or Kidney-Combined Organ Transplantation. Transplantation 2010.
44. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914-56.